Overview
- A definitive agreement announced Thursday prices Catalyst at $31.50 per share in cash, valuing the company at about $4.1 billion.
- Both boards unanimously approved the deal, which is expected to close in the third quarter of 2026 pending customary approvals.
- Angelini says Blackstone funds will participate in the transaction, and BNP Paribas is underwriting the financing as Sole Global Coordinator.
- The acquisition adds FDA‑approved rare‑disease and neurology drugs to Angelini’s platform, including Firdapse for Lambert‑Eaton myasthenic syndrome, Agamree for Duchenne muscular dystrophy, and U.S. rights to Fycompa for certain seizures.
- Catalyst shareholders gain an immediate cash premium of 21% to the unaffected April 22 price and 28% to the 30‑day average, while Angelini plans to integrate Catalyst’s U.S. commercial team to expand its brain‑health and rare‑disease reach.